Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18883 participants.

Also called NCT02810704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 18,883 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02810704
Other papers using this trial's data
  • Prevention of Venous Thromboembolism after Total Hip or Knee Replacement The New England journal of medicine, 2026-11-12 DOI, PubMed 43013818

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02810704. Randomized; no masking; primary purpose supportive care. Start 2016-12 (actual); primary completion 2025-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
Acronym
PEPPER
Condition
Venous Thrombosis
Intervention (Drug)
Enteric Coated Aspirin
Intervention (Drug)
Warfarin
Intervention (Drug)
Rivaroxaban
Lead sponsor
Dartmouth-Hitchcock Medical Center (class: other)
Collaborator
Patient-Centered Outcomes Research Institute (class: other)
Collaborator
University of Maryland, Baltimore (class: other)
Collaborator
Brigham and Women's Hospital (class: other)
Collaborator
Northwestern University (class: other)
Collaborator
Medical University of South Carolina (class: other)

Record details

Record id
cardio:ct-nct02810704
Content hash
139bbb89ee5dc5b844d6f1b3ed46fa9a4291e9fc79b4a1b1293bbdb2de8a4b47